MX2012004780A - Inhibidores de akt. - Google Patents

Inhibidores de akt.

Info

Publication number
MX2012004780A
MX2012004780A MX2012004780A MX2012004780A MX2012004780A MX 2012004780 A MX2012004780 A MX 2012004780A MX 2012004780 A MX2012004780 A MX 2012004780A MX 2012004780 A MX2012004780 A MX 2012004780A MX 2012004780 A MX2012004780 A MX 2012004780A
Authority
MX
Mexico
Prior art keywords
formula
akt inhibitors
compounds
present
provides
Prior art date
Application number
MX2012004780A
Other languages
English (en)
Spanish (es)
Inventor
Douglas Wade Beight
Jason Scott Sawyer
Saravanan Parthasarathy
Timothy Paul Burkholder
Mark Edward Rempala
Joshua Ryan Clayton
Marijean Eggen
Deidre Michelle Johns
Huaxing Pei
Kenneth James Junior Henry
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2012004780A publication Critical patent/MX2012004780A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2012004780A 2009-10-23 2010-10-20 Inhibidores de akt. MX2012004780A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25430809P 2009-10-23 2009-10-23
PCT/US2010/053295 WO2011050016A1 (en) 2009-10-23 2010-10-20 Akt inhibitors

Publications (1)

Publication Number Publication Date
MX2012004780A true MX2012004780A (es) 2012-08-23

Family

ID=43467018

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004780A MX2012004780A (es) 2009-10-23 2010-10-20 Inhibidores de akt.

Country Status (12)

Country Link
US (1) US8436002B2 (OSRAM)
EP (1) EP2491032B1 (OSRAM)
JP (1) JP5581390B2 (OSRAM)
KR (1) KR101398268B1 (OSRAM)
CN (1) CN102574852B (OSRAM)
AU (1) AU2010310786B2 (OSRAM)
BR (1) BR112012011328A2 (OSRAM)
CA (1) CA2778291C (OSRAM)
EA (1) EA020151B1 (OSRAM)
ES (1) ES2465094T3 (OSRAM)
MX (1) MX2012004780A (OSRAM)
WO (1) WO2011050016A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2588878T3 (es) 2012-05-17 2016-11-07 Array Biopharma, Inc. Proceso para preparar compuestos de ciclopentilpirimidina hidroxilada
HRP20180948T1 (hr) 2012-05-17 2018-08-10 Genentech, Inc. Postupak za proizvodnju aminokiselinskih spojeva
NZ702935A (en) 2012-05-17 2017-02-24 Genentech Inc Process for making hydroxylated cyclopentylpyrimidine compounds
EP3719014A1 (en) 2012-05-17 2020-10-07 Genentech, Inc. Solid forms of an akt inhibiting pyrimidinyl-cyclopentane compound, compositions and methods thereof
CA2873661C (en) 2012-05-17 2020-07-21 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
ES2656096T3 (es) * 2012-11-16 2018-02-23 Merck Patent Gmbh Nuevos derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa
AU2014228385B2 (en) * 2013-03-11 2018-08-09 Merck Patent Gmbh 6-[4-(1-H-imidazol-2-yl]piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
US10526660B2 (en) 2013-09-12 2020-01-07 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating Waldenstrom's macroglobulinemia
GB201401198D0 (en) 2014-01-24 2014-03-12 Bial Portela & Ca Sa Process for the syntheis of substituted urea compounds
EP3110509B1 (en) 2014-02-28 2020-08-19 Merck Sharp & Dohme Corp. Treating cancer with a combination comprising dinaciclib
MA45048A (fr) * 2016-05-20 2019-03-27 Taiho Pharmaceutical Co Ltd Nouveau dérivé de 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one
CN113272304B (zh) * 2019-01-29 2024-03-29 南京正大天晴制药有限公司 Akt抑制剂
WO2021228223A1 (zh) * 2020-05-15 2021-11-18 南京正大天晴制药有限公司 氘代akt激酶抑制剂
CA3186568A1 (en) * 2020-07-22 2022-01-27 Changyou MA Salt of dihydropyrido[2,3-d]pyrimidinone derivative, preparation method therefor, and use thereof
US20230271958A1 (en) * 2020-07-22 2023-08-31 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. SALT AND CRYSTAL FORM OF DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATE
US20230321108A1 (en) * 2020-07-22 2023-10-12 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Unit dosage composition of akt inhibitor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
WO2003064383A2 (en) 2002-02-01 2003-08-07 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
US8076338B2 (en) 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
JP5111113B2 (ja) * 2004-12-13 2012-12-26 サネシス ファーマシューティカルズ, インコーポレイテッド Rafキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン
JP5274842B2 (ja) * 2004-12-28 2013-08-28 エグゼリクシス, インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター(p70S6K、Akt−1およびAkt−2)としての[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジンまたは[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジン化合物
ES2360232T3 (es) 2005-06-29 2011-06-02 Compumedics Limited Conjunto sensor con puente conductor.
EP3719018B1 (en) 2006-04-25 2025-08-27 Astex Therapeutics Ltd Purine and deazapurine derivatives as pharmaceutical compounds
JP2009534456A (ja) * 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
AR074072A1 (es) * 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme

Also Published As

Publication number Publication date
AU2010310786B2 (en) 2014-03-27
JP5581390B2 (ja) 2014-08-27
ES2465094T3 (es) 2014-06-05
AU2010310786A1 (en) 2012-04-19
KR101398268B1 (ko) 2014-05-23
WO2011050016A1 (en) 2011-04-28
US20120149684A1 (en) 2012-06-14
CA2778291C (en) 2014-02-11
CN102574852A (zh) 2012-07-11
BR112012011328A2 (pt) 2016-11-22
EA201270590A1 (ru) 2012-09-28
CN102574852B (zh) 2014-06-25
EP2491032B1 (en) 2014-04-16
US8436002B2 (en) 2013-05-07
KR20120068941A (ko) 2012-06-27
CA2778291A1 (en) 2011-04-28
JP2013508382A (ja) 2013-03-07
EP2491032A1 (en) 2012-08-29
EA020151B1 (ru) 2014-09-30

Similar Documents

Publication Publication Date Title
MX2012004780A (es) Inhibidores de akt.
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
MY153915A (en) Organic compounds
IN2012DN03883A (OSRAM)
MY161461A (en) Akt and p70 s6 kinase inhibitors
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
TN2011000673A1 (en) Bace inhibitors
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
MX2009000884A (es) Derivados de piridizinona.
PH12015501484A1 (en) Heteroaryl compounds and uses thereof
MY150542A (en) Cmet inhibitors
UA99284C2 (ru) ИНГИБИТОРЫ р70 S6-КИНАЗЫ
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
WO2010077730A3 (en) Indanone inhibitors of acetylcholinesterase
MX2011010046A (es) Derivados de diaminopteridina.
WO2010059639A3 (en) Hydroxyadamantyl inhibitors of dipeptidylpeptidase iv
MX2012004282A (es) Composiciones farmaceuticas.
TN2010000583A1 (en) Organic compounds
TN2011000020A1 (en) cMET INHIBITORS

Legal Events

Date Code Title Description
FG Grant or registration